MDXH
MDxHealth SA (MDXH)
Healthcare • NASDAQ • $2.00-0.50%
- Symbol
- MDXH
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Price
- $2.00
- Daily Change
- -0.50%
- Market Cap
- $102.73M
- Trailing P/E
- N/A
- Forward P/E
- -15.38
- 52W High
- $5.33
- 52W Low
- $1.70
- Analyst Target
- $7.40
- Dividend Yield
- N/A
- Beta
- -510468.06
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through u…
Company websiteResearch MDXH on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.